FR3110166B1 - Nouvelles compositions immunogenes et leur application pour la preparation de vaccins contre l’hepatite c et l’hepatite b - Google Patents

Nouvelles compositions immunogenes et leur application pour la preparation de vaccins contre l’hepatite c et l’hepatite b Download PDF

Info

Publication number
FR3110166B1
FR3110166B1 FR2004848A FR2004848A FR3110166B1 FR 3110166 B1 FR3110166 B1 FR 3110166B1 FR 2004848 A FR2004848 A FR 2004848A FR 2004848 A FR2004848 A FR 2004848A FR 3110166 B1 FR3110166 B1 FR 3110166B1
Authority
FR
France
Prior art keywords
hepatitis
immunogenic compositions
preparation
new immunogenic
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR2004848A
Other languages
English (en)
Other versions
FR3110166A1 (fr
Inventor
Elodie Beaumont
Elsa Gomez-Escobar
Christophe Hourioux
Romuald Patient
Philippe Roingeard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Regional Universitaire de Tours
Universite de Tours
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Regional Universitaire de Tours
Universite de Tours
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Centre Hospitalier Regional Universitaire de Tours, Universite de Tours filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to FR2004848A priority Critical patent/FR3110166B1/fr
Priority to PCT/EP2021/062853 priority patent/WO2021229065A1/fr
Publication of FR3110166A1 publication Critical patent/FR3110166A1/fr
Application granted granted Critical
Publication of FR3110166B1 publication Critical patent/FR3110166B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

TITRE : NOUVELLES COMPOSITIONS IMMUNOGENES ET LEUR APPLICATION POUR LA PREPARATION DE VACCINS CONTRE L’HEPATITE C ET L’HEPATITE B L’invention a pour objet de nouvelles compositions immunogènes comprenant un mélange de particules d’enveloppes sous-virales chimères entre les protéines d’enveloppe du virus de l’hépatite B (HBV, pour Hepatitis B virus) et du virus de l’hépatite C (HCV, pour Hepatitis C virus). L’invention a également pour objet l’utilisation de ces nouvelles compositions immunogènes, en tant que vaccin, pour la prévention et/ou le traitement prophylactique et/ou thérapeutique de l’hépatite C, ou pour la prévention et/ou le traitement prophylactique et/ou thérapeutique de l’hépatite B, ou pour la prévention et/ou le traitement prophylactique et/ou thérapeutique de l’hépatite C et de l’hépatite B. Pas de figure
FR2004848A 2020-05-15 2020-05-15 Nouvelles compositions immunogenes et leur application pour la preparation de vaccins contre l’hepatite c et l’hepatite b Expired - Fee Related FR3110166B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR2004848A FR3110166B1 (fr) 2020-05-15 2020-05-15 Nouvelles compositions immunogenes et leur application pour la preparation de vaccins contre l’hepatite c et l’hepatite b
PCT/EP2021/062853 WO2021229065A1 (fr) 2020-05-15 2021-05-14 Nouvelles compositions immunogenes et leur application pour la preparation de vaccins contre l'hepatite c et l'hepatite b

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2004848A FR3110166B1 (fr) 2020-05-15 2020-05-15 Nouvelles compositions immunogenes et leur application pour la preparation de vaccins contre l’hepatite c et l’hepatite b
FR2004848 2020-05-15

Publications (2)

Publication Number Publication Date
FR3110166A1 FR3110166A1 (fr) 2021-11-19
FR3110166B1 true FR3110166B1 (fr) 2022-04-29

Family

ID=73038024

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2004848A Expired - Fee Related FR3110166B1 (fr) 2020-05-15 2020-05-15 Nouvelles compositions immunogenes et leur application pour la preparation de vaccins contre l’hepatite c et l’hepatite b

Country Status (2)

Country Link
FR (1) FR3110166B1 (fr)
WO (1) WO2021229065A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740323B1 (en) * 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
AUPQ912000A0 (en) * 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
FR2932388B1 (fr) * 2008-06-17 2013-03-29 Univ Rabelais Francois Nouvelles proteines de fusion et leur application pour la preparation de vaccins contre l'hepatite c

Also Published As

Publication number Publication date
FR3110166A1 (fr) 2021-11-19
WO2021229065A1 (fr) 2021-11-18

Similar Documents

Publication Publication Date Title
Rawat et al. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies
Roy et al. Virus‑like particles as a vaccine delivery system: Myths and facts
Velasquez et al. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine
HK1074578A1 (en) Packaged virus-like particles in combination with cpg for use as adjuvants with allergens: method of preparation and use
US8216595B2 (en) Powerful vaccine composition comprising lipopeptide and poly I:C as an adjuvant
Tumban et al. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2
Zhang et al. Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis
CN115190911B (zh) 对sars冠状病毒2具有免疫原性的组合物、其制备方法和用途
JP2011057692A (ja) ウエストナイルワクチン
BR0113301A (pt) Composição de vacina em dose sólida oral
JP2018038405A (ja) 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド
Liu et al. Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines
RU2008114841A (ru) Фармацевтическая композиция, способная индуцировать защитный иммунный ответ против вируса денге, содержащая капсидный белок этого вируса
WO2022140364A3 (fr) Vaccins contre le virus de la peste porcine africaine (ppa)
Collen et al. Heterotypic recognition of recombinant FMDV proteins by bovine T-cells: the polymerase (P3Dpol) as an immunodominant T-cell immunogen
Cai et al. Enhanced immune responses to E2 protein and DNA formulated with ISA 61 VG administered as a DNA prime–protein boost regimen against bovine viral diarrhea virus
CA2352777C (fr) Preparations renfermant des particules immunostimulantes de type virus administrees par voie muqueuse
FR3110166B1 (fr) Nouvelles compositions immunogenes et leur application pour la preparation de vaccins contre l’hepatite c et l’hepatite b
Silveira et al. Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice
Farnós et al. The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice
WO2023012824A1 (fr) Synergie de l'immunogénicité par l'intermédiaire d'une immunisation parentale et mucosale combinée contre le covid-19
WO2005016246A3 (fr) Particules virales modifiees possedant des proprietes immunogenes et une teneur limitee en lipides utiles pour traiter et prevenir des maladies infectieuses
MX2022004869A (es) Vacuna de particulas similares al virus chikungunya y metodos de uso de la misma.
JP2016514114A5 (fr)
Morelli et al. ISCOMATRIX adjuvant in the development of prophylactic and therapeutic vaccines

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20211119

PLFP Fee payment

Year of fee payment: 3

ST Notification of lapse

Effective date: 20240105